8-K/AAcquisitions & DispositionsExhibits & Filings

DANAHER CORP /DE/ 8-K/A Report, Acquisition Completed (May 21, 2020)

Filed May 21, 2020For Securities:DHR

Summary

This 8-K Amendment from Danaher Corporation (DHR) provides crucial pro forma financial information related to its acquisition of General Electric Company's Biopharma business, which was completed on March 31, 2020. This filing serves to supplement the initial 8-K report by including the necessary financial statements that were initially omitted, allowing investors to better understand the financial impact and combined entity's potential performance post-acquisition. The pro forma financial statements offer a hypothetical view of the combined companies' financial position and results as if the acquisition had occurred at an earlier date. This is essential for investors to assess the scale of the transaction, its potential synergies, and its expected contribution to Danaher's overall revenue and profitability. Investors should review these pro forma statements to evaluate the strategic fit and financial accretion of this significant acquisition.

Key Highlights

  • 1Amendment to a previous 8-K filing, providing omitted pro forma financial information.
  • 2The filing's primary purpose is to include unaudited pro forma condensed combined financial statements for the Biopharma business acquisition.
  • 3Acquisition of GE's Biopharma business was completed on March 31, 2020.
  • 4The pro forma financial information is required by Item 9.01 of Form 8-K.
  • 5This data allows for a clearer understanding of the financial implications of combining Danaher with GE's Biopharma assets.
  • 6Investors can use this pro forma data to assess the potential financial performance and impact of the acquired business on Danaher.

Frequently Asked Questions

The main purpose of this 8-K/A filing is to provide the unaudited pro forma condensed combined financial statements related to Danaher Corporation's acquisition of General Electric Company's Biopharma business. These financial statements were not included in the original 8-K filing and are now being provided as required.

The acquisition of the Biopharma business of General Electric Company was completed on March 31, 2020.

The pro forma financial statements were initially omitted from the original 8-K filing in reliance on specific provisions of Form 8-K (Items 9.01(a)(4) and 9.01(b)(2)), which allow for their later submission. This amendment serves to fulfill that requirement.

Pro forma financial statements provide a hypothetical view of the combined company's financial results and position as if the acquisition had occurred at an earlier date. This helps investors assess the potential financial impact, scale, and expected synergies of the acquired business on Danaher's overall financial performance.